Abstract
Cancer vaccines have been developed using a wide range of technologies, yielding agents ranging from nonspecific immunostimulants through to highly technical peptide- and DNA-based candidates. There are many technical challenges involved in even the most basic decisions in vaccine development, such as the choice of antigen, formulation, adjuvant, route of… (More)